ストックスクリーナーアプリを入手
11.32
2.16%
-0.25
前日終値:
$11.57
開ける：
$11.57
24時間の取引高:
4.54M
Relative Volume:
0.57
時価総額：
$3.67B
収益：
$79.21M
当期純損益:
$-143.96M
株価収益率:
-23.60
EPS:
-0.4796
ネットキャッシュフロー:
$-189.60M
1週間 パフォーマンス:
-0.53%
1か月 パフォーマンス:
+89.61%
6か月 パフォーマンス:
+272.37%
1年 パフォーマンス:
+163.26%
1日の値動き範囲:
$11.14
$11.80
1週間の範囲:
$10.60
$12.15
52週間の値動き範囲:
$2.745
$12.15
Abcellera Biologics Inc Stock (ABCL) Company Profile
Compare ABCL vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ABCL
Abcellera Biologics Inc
|
11.32 | 3.75B | 79.21M | -143.96M | -189.60M | -0.4796 |
VRTX
Vertex Pharmaceuticals Inc
|
548.05 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
834.04 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,039.78 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.13 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.46 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-07 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-07-07 | 再開されました | Leerink Partners | Outperform |
| 2024-08-20 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2024-02-22 | アップグレード | The Benchmark Company | Hold → Buy |
| 2023-12-05 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2023-11-06 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2023-10-13 | 再開されました | Piper Sandler | Overweight |
| 2023-02-28 | 開始されました | Cowen | Outperform |
| 2022-12-15 | 開始されました | Goldman | Buy |
| 2022-11-16 | 開始されました | Truist | Buy |
| 2021-12-21 | 開始されました | The Benchmark Company | Buy |
| 2021-11-19 | 開始されました | Piper Sandler | Overweight |
| 2021-01-05 | 開始されました | BMO Capital Markets | Outperform |
| 2021-01-05 | 開始されました | Berenberg | Buy |
| 2021-01-05 | 開始されました | Credit Suisse | Outperform |
| 2021-01-05 | 開始されました | SVB Leerink | Outperform |
| 2021-01-05 | 開始されました | Stifel | Buy |
すべてを表示
Abcellera Biologics Inc (ABCL) 最新ニュース
ABCL StockAbCellera Biologics Inc Stock Breaking News Today | ABCL Stock Price Punaises (dD09m2oJ3D) - Mshale
AbCellera Biologics (ABCL) Reports Phase 2 Success, Is It Still A Bargain? - simplywall.st
Abcellera director John S. Montalbano acquires common shares worth $110,300 - Bitget
AbCellera Biologics Director John S. Montalbano Acquires 10,000 Shares on August 18, 2026 - Kalkine Media
AbCellera Biologics | 4: Statement of changes in beneficial ownership of securities-Director Montalbano John S. - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
AbCellera (ABCL) Q2 2026 Earnings Call Transcript - AOL.com
Abcellera Biologics stock hits 52-week high at 11.51 USD - Investing.com
Abcellera Biologics stock hits 52-week high at 11.51 USD By Investing.com - Investing.com India
Why AbCellera (ABCL) Is Up 64.2% After Menopause Trial Win, Equity Raise And Vertex Deal - simplywall.st
AbCellera (ABCL) Soars 64% as Drug Candidate Holds Huge Market Opportunity - Yahoo Finance
AbCellera Biologics Stock (ABCL) Opinions on Positive Phase 2 Trial Results - Quiver Quantitative
Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough? - Yahoo Finance
AbCellera Biologics Inc. • Robinhood Token (ABCL) Price, MarketCap, Charts and Fundamentals Info - BeInCrypto
AbCellera CFO Andrew Booth Acquires 37,200 Shares at $10.32 Each - Kalkine Media
AbCellera Biologics Director Michael R. Hayden Acquires 46,387 Shares at $10.37 Average Price - Kalkine Media
AbCellera Biologics | 4: Statement of changes in beneficial ownership of securities-Officer Booth Andrew - Moomoo
AbCellera Biologics Stock 6-Day Winning Spree: Stock Climbs 85% - Trefis
6 Green Days In A Row: AbCellera Biologics Stock Is Up 85% - Trefis
ABCL News | ABCELLERA BIOLOGICS INC (NASDAQ:ABCL) - ChartMill
AbCellera prices US $200M offering at US $9.75 a share - Private Capital Journal
AbCellera Biologics | 424B5: Prospectus - Moomoo
AbCellera Biologics | 4: Statement of changes in beneficial ownership of securities-Director Hayden Michael R - Moomoo
National CineMedia Posts Downbeat Q2 Results, Joins Borr Drilling, AbCellera Biologics And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session - Sahm
AbCellera Director Michael R. Hayden Donates 50,000 Shares to Charity via Genworks 2 Consulting - Kalkine Media
AbCellera Biologics Announces Oversubscribed $200 Million Offering - TipRanks
AbCellera Enters Underwriting Agreement for $187M Equity Offering With Jefferies, J.P. Morgan - TradingView
AbCellera Biologics Inc. • Robinhood Token (ABCL) Price Prediction for 2026 to 2031 - Bybit
AbCellera Biologics (NASDAQ:ABCL) Sees Large Volume IncreaseTime to Buy? - MarketBeat
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile - AOL.com
Funding Roundup: Silence Therapeutics, AbCellera Announce IPO Pricing, Beyang, Remepy Close Series A Financing - Pharmaceutical Executive
Revenue Downgrade: Here's What Analysts Forecast For AbCellera Biologics Inc. (NASDAQ:ABCL) - 富途牛牛
Abcellera Biologics Inc Nasdaq ABCL Canada F-35 Fighter Jet Purchase (hA9yM7fsuE) - Mshale
ABCL Stock Clocks Best Week Since February On Clinical Data Anticipation, Baker Bros Stake Boost - Stocktwits
AbCellera prices $200 million public offering at $9.75/share - Investing.com
ABCL Looks 82.6% Overvalued on GF Value™ - GuruFocus
AbCellera prices $200 million public offering at $9.75/share By Investing.com - Investing.com Nigeria
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants - Business Wire
AbCellera Biologics stock analysis: momentum vs. fundamentals By Investing.com - Investing.com Canada
AbCellera Biologics stock analysis: momentum vs. fundamentals - Investing.com
What's Going on With AbCellera Biologics Stock On Wednesday? - Benzinga
AbCellera Biologics (NASDAQ:ABCL) Shares Gap DownHere's Why - MarketBeat
National CineMedia Posts Downbeat Q2 Results, Joins Borr Drilling, AbCellera Biologics And Other Big Stoc - Benzinga
AbCellera offers up USD 200m in stock to support NK3 menopause antibody - AllSci
AbCellera Biologics Inc. (NASDAQ:ABCL) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
AbCellera’s ABCL635 Meets Primary Endpoints in Phase 2 for Menopause Symptoms - The Clinical Trial Vanguard
AbCellera Biologics (ABCL) Stock Sees Fair Value Lift After Clinical Data And Jazz Deal - finance.yahoo.com
AbCellera Biologics (ABCL) On ABCL635 Trial Results And A Richer Valuation Story - simplywall.st
Truist raises AbCellera stock price target on trial results By Investing.com - Investing.com South Africa
AbCellera launches $200-million equity offering on heels of strong menopause trial results - The Globe and Mail
AbCellera launches $200 million public offering of common shares By Investing.com - Investing.com UK
Abcellera Biologics Inc (ABCL) 財務データ
収益
当期純利益
現金流量
EPS
1.21%
1.07%
大文字化:
|
ボリューム (24 時間):